Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

SHREVEPORT, La. - Many people are using cheaper versions of popular weight-loss shots like Ozempic and Wegovy.

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

The injectable drug Ozempic is shown Saturday ... The 503As, however, could exploit a loophole: They can still make semaglutide copies that are not "essential copies" of the drug.

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight-loss drugs was intended to shut the door on that booming market. It hasn’t exactly worked out that way.